CORT RSI Chart
Last 7 days
6.5%
Last 30 days
4.9%
Last 90 days
13.0%
Trailing 12 Months
6.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 523.5M | 0 | 0 | 0 |
2023 | 413.8M | 428.2M | 450.0M | 482.4M |
2022 | 380.2M | 392.0M | 397.6M | 401.9M |
2021 | 340.1M | 343.1M | 352.9M | 366.0M |
2020 | 334.9M | 351.2M | 356.0M | 353.9M |
2019 | 258.4M | 268.4M | 285.4M | 306.5M |
2018 | 189.3M | 216.0M | 237.7M | 251.2M |
2017 | 92.9M | 108.7M | 129.7M | 159.2M |
2016 | 56.2M | 64.0M | 72.5M | 81.3M |
2015 | 32.2M | 38.4M | 44.3M | 50.3M |
2014 | 13.0M | 17.0M | 21.7M | 26.6M |
2013 | 5.0M | 6.0M | 7.6M | 10.4M |
2012 | 2.4M | 2.7M | 3.0M | 3.3M |
2011 | 0 | 0 | 1.8M | 2.1M |
2010 | 0 | 566.0K | 1.0M | 1.5M |
2009 | 0 | 0 | 0 | 101.0K |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2024 | lyon joseph douglas | sold | -281,580 | 26.00 | -10,830 | see remarks |
May 02, 2024 | lyon joseph douglas | acquired | 122,920 | 11.35 | 10,830 | see remarks |
May 01, 2024 | swisher daniel n jr | sold | -50,798 | 23.09 | -2,200 | - |
May 01, 2024 | swisher daniel n jr | acquired | 12,892 | 5.86 | 2,200 | - |
Apr 10, 2024 | mahoney david l | sold (taxes) | -52,217 | 23.8 | -2,194 | - |
Apr 10, 2024 | mahoney david l | sold | - | - | -27,806 | - |
Apr 10, 2024 | mahoney david l | acquired | 52,200 | 1.74 | 30,000 | - |
Apr 10, 2024 | mahoney david l | acquired | - | - | 27,806 | - |
Apr 04, 2024 | lyon joseph douglas | sold | -141,524 | 26.0011 | -5,443 | see remarks |
Apr 04, 2024 | lyon joseph douglas | acquired | 61,778 | 11.35 | 5,443 | see remarks |
Which funds bought or sold CORT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | ASSETMARK, INC | added | 1.56 | -386,935 | 1,435,220 | -% |
May 07, 2024 | SEI INVESTMENTS CO | added | 207 | 902,061 | 1,552,350 | -% |
May 07, 2024 | Headlands Technologies LLC | reduced | -71.14 | -36,606 | 10,555 | -% |
May 07, 2024 | QRG CAPITAL MANAGEMENT, INC. | reduced | -5.86 | -694,784 | 1,879,680 | 0.02% |
May 07, 2024 | Susquehanna Portfolio Strategies, LLC | sold off | -100 | -355,656 | - | -% |
May 07, 2024 | Swiss National Bank | added | 0.7 | -1,221,940 | 4,356,990 | -% |
May 07, 2024 | MONTAG A & ASSOCIATES INC | unchanged | - | -3,952 | 13,653 | -% |
May 07, 2024 | M&T Bank Corp | new | - | 291,076 | 291,076 | -% |
May 07, 2024 | Arizona State Retirement System | reduced | -1.18 | -184,865 | 606,575 | -% |
May 07, 2024 | Inspire Investing, LLC | sold off | -100 | -794,526 | - | -% |
Unveiling Corcept Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Corcept Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.7B | 6.8B | -7.83 | 6.82 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.3B | 2.0B | -58.01 | 9.62 | ||||
BMRN | 15.5B | 2.5B | 75.6 | 6.28 | ||||
INCY | 12.0B | 3.8B | 16.12 | 3.19 | ||||
MID-CAP | ||||||||
BBIO | 5.2B | 107.9M | -9.48 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.3 | 9.79 | ||||
AXSM | 3.6B | 251.0M | -12.15 | 14.35 | ||||
ARWR | 3.1B | 240.7M | -10.53 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.95 | 3.88 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 411.3M | 26.68 | 4.22 | ||||
NVAX | 625.6M | 983.7M | -1.15 | 0.64 | ||||
CRBP | 451.6M | 881.7K | -13.38 | 481.06 | ||||
INO | 257.1M | 4.9M | -1.9 | 52.83 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
Corcept Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 8.4% | 147 | 135 | 124 | 118 | 106 | 103 | 102 | 103 | 94.00 | 99.00 | 96.00 | 92.00 | 79.00 | 86.00 | 86.00 | 89.00 | 93.00 | 88.00 | 82.00 | 72.00 | 65.00 |
Costs and Expenses | 13.1% | 117 | 104 | 92.00 | 88.00 | 91.00 | 81.00 | 70.00 | 72.00 | 67.00 | 62.00 | 60.00 | 60.00 | 60.00 | 55.00 | 62.00 | 53.00 | 56.00 | 53.00 | 49.00 | 48.00 | 46.00 |
S&GA Expenses | 19.3% | 56.00 | 47.00 | 45.00 | 43.00 | 49.00 | 42.00 | 35.00 | 38.00 | 38.00 | 32.00 | 31.00 | 30.00 | 30.00 | 26.00 | 27.00 | 26.00 | 28.00 | 27.00 | 24.00 | 25.00 | 24.00 |
R&D Expenses | 6.9% | 59.00 | 55.00 | 46.00 | 43.00 | 41.00 | 37.00 | 33.00 | 33.00 | 28.00 | 29.00 | 28.00 | 28.00 | 29.00 | 28.00 | 34.00 | 26.00 | 26.00 | 24.00 | 23.00 | 22.00 | 20.00 |
EBITDA Margin | 4.3% | 0.27* | 0.26* | 0.25* | 0.26* | 0.26* | 0.29* | 0.33* | 0.33* | 0.35* | 0.34* | 0.34* | 0.32* | - | - | - | - | - | - | - | - | - |
Income Taxes | 33.5% | 7.00 | 5.00 | 5.00 | 5.00 | 3.00 | 8.00 | -1.60 | 5.00 | 4.00 | 5.00 | 6.00 | 6.00 | -3.55 | 5.00 | 4.00 | 8.00 | 9.00 | 7.00 | 8.00 | 6.00 | 2.00 |
Earnings Before Taxes | -4.9% | 35.00 | 37.00 | 36.00 | 33.00 | 18.00 | 24.00 | 33.00 | 32.00 | 27.00 | 37.00 | 36.00 | 32.00 | 20.00 | 31.00 | 25.00 | 36.00 | 39.00 | 36.00 | 34.00 | 26.00 | 20.00 |
EBT Margin | 4.4% | 0.27* | 0.26* | 0.25* | 0.25* | 0.26* | 0.29* | 0.32* | 0.34* | 0.35* | 0.34* | 0.34* | 0.32* | - | - | - | - | - | - | - | - | - |
Net Income | -11.5% | 28.00 | 31.00 | 31.00 | 28.00 | 16.00 | 17.00 | 35.00 | 27.00 | 23.00 | 32.00 | 30.00 | 27.00 | 23.00 | 26.00 | 22.00 | 28.00 | 30.00 | 29.00 | 26.00 | 20.00 | 18.00 |
Net Income Margin | 2.5% | 0.23* | 0.22* | 0.20* | 0.22* | 0.23* | 0.25* | 0.29* | 0.29* | 0.29* | 0.31* | 0.30* | 0.28* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 303.5% | 24.00 | 6.00 | 53.00 | 42.00 | 26.00 | 33.00 | 33.00 | 18.00 | 35.00 | 49.00 | 49.00 | 44.00 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 5.5% | 656 | 622 | 594 | 525 | 618 | 583 | 533 | 496 | 468 | 424 | 585 | 568 | 552 | 572 | 534 | 498 | 445 | 412 | 367 | 329 | 320 |
Current Assets | 9.8% | 503 | 459 | 432 | 433 | 534 | 499 | 452 | 419 | 388 | 266 | 402 | 411 | 410 | 479 | 463 | 438 | 345 | 307 | 267 | 233 | 217 |
Cash Equivalents | 10.5% | 150 | 136 | 112 | 172 | 300 | 66.00 | 50.00 | 35.00 | 62.00 | 78.00 | 95.00 | 95.00 | 52.00 | 76.00 | 31.00 | 59.00 | 84.00 | 31.00 | 45.00 | 58.00 | 50.00 |
Inventory | -7.0% | 7.00 | 8.00 | 8.00 | 7.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
Net PPE | -34.9% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -5.9% | 108 | 115 | 132 | 103 | 88.00 | 82.00 | 60.00 | 54.00 | 60.00 | 48.00 | 45.00 | 46.00 | 42.00 | 48.00 | 44.00 | 44.00 | 36.00 | 41.00 | 33.00 | 31.00 | 34.00 |
Current Liabilities | -7.0% | 97.00 | 105 | 122 | 93.00 | 79.00 | 72.00 | 53.00 | 49.00 | 57.00 | 48.00 | 45.00 | 45.00 | 41.00 | 47.00 | 43.00 | 42.00 | 34.00 | 39.00 | 32.00 | 30.00 | 34.00 |
Shareholder's Equity | 8.1% | 548 | 507 | 462 | 422 | 530 | 502 | 473 | 442 | 408 | 376 | 540 | 523 | 511 | 523 | 490 | 454 | 409 | 371 | 334 | 298 | 286 |
Retained Earnings | 6.9% | 430 | 403 | 371 | 340 | 312 | 296 | 280 | 245 | 218 | 195 | 163 | 132 | 106 | 82.00 | 56.00 | 35.00 | 7.00 | -23.55 | -52.94 | -79.28 | -99.46 |
Additional Paid-In Capital | 2.7% | 758 | 739 | 722 | 696 | 680 | 662 | 649 | 626 | 609 | 591 | 571 | 554 | 536 | 516 | 496 | 482 | 466 | 457 | 447 | 437 | 427 |
Shares Outstanding | -0.6% | 103 | 103 | 102 | 105 | 108 | 108 | 107 | 106 | 106 | 116 | 116 | 117 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 1,827 | - | - | - | 2,058 | - | - | - | 2,122 | - | - | - | 1,633 | - | - | - | 1,071 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 303.5% | 23,756 | 5,887 | 52,909 | 42,286 | 25,957 | 33,388 | 33,648 | 18,040 | 35,247 | 49,427 | 48,704 | 44,339 | 25,422 | 35,071 | 30,444 | 53,186 | 33,269 | 48,454 | 38,427 | 25,555 | 23,681 |
Share Based Compensation | 1.4% | 13,249 | 13,065 | 12,876 | 11,858 | 11,141 | 10,521 | 10,554 | 10,606 | 10,761 | 10,810 | 10,952 | 11,068 | 10,101 | 8,430 | 8,702 | 8,489 | 7,918 | 7,610 | 7,271 | 7,736 | 6,696 |
Cashflow From Investing | -152.7% | -9,014 | 17,098 | -109,570 | -24,097 | 207,475 | -17,241 | -4,790 | -41,800 | -50,496 | 140,471 | -25,803 | 24,742 | -3,284 | 11,220 | -64,273 | -85,944 | 19,734 | -61,989 | -54,316 | -1,156 | -367 |
Cashflow From Financing | -170.9% | -543 | 766 | -3,916 | -145,754 | 181 | -61.00 | -13,961 | -2,756 | -506 | -206,969 | -23,643 | -26,032 | -45,947 | -661 | 5,866 | 6,804 | 205 | -144 | 2,696 | -15,908 | -15,289 |
Buy Backs | - | 476 | - | - | 145,428 | - | - | - | - | - | - | 25,774 | 29,170 | 33,541 | 9,670 | - | - | 275 | - | - | 17,420 | 13,555 |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Statement of Comprehensive Income [Abstract] | ||
Product revenue, net | $ 146,808 | $ 105,654 |
Operating expenses: | ||
Cost of sales | 2,535 | 1,386 |
Research and development | 58,505 | 40,851 |
Selling, general and administrative | 56,268 | 48,564 |
Total operating expenses | 117,308 | 90,801 |
Income from operations | 29,500 | 14,853 |
Interest and other income | 5,493 | 3,581 |
Income before income taxes | 34,993 | 18,434 |
Income tax expense | (7,231) | (2,555) |
Net income | 27,762 | 15,879 |
Net income attributable to common stockholders, basic | 27,514 | 15,807 |
Net income attributable to common stockholders, diluted | $ 27,514 | $ 15,807 |
Basic net income per share (in dollars per share) | $ 0.27 | $ 0.15 |
Diluted net income per share (in dollars per share) | $ 0.25 | $ 0.14 |
Weighted-average shares outstanding used in computing net income per common share | ||
Basic (in shares) | 102,791 | 107,885 |
Diluted (in shares) | 109,915 | 115,425 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 149,750 | $ 135,551 |
Short-term marketable securities | 261,011 | 232,670 |
Trade receivables, net of allowances | 61,518 | 41,123 |
Insurance recovery receivable related to Melucci litigation (Note 4) | 0 | 14,000 |
Inventory | 7,190 | 7,730 |
Prepaid expenses and other current assets | 23,898 | 27,562 |
Total current assets | 503,367 | 458,636 |
Strategic inventory | 7,846 | 8,244 |
Operating lease right-of-use asset | 61 | 120 |
Property and equipment, net | 127 | 195 |
Long-term marketable securities | 40,276 | 57,176 |
Other assets | 6,388 | 6,541 |
Deferred tax assets, net | 97,870 | 90,605 |
Total assets | 655,935 | 621,517 |
Current liabilities: | ||
Accounts payable | 12,557 | 17,396 |
Accrued research and development expenses | 24,825 | 21,330 |
Accrued and other liabilities | 59,744 | 51,628 |
Accrued settlement related to Melucci litigation (Note 4) | 0 | 14,000 |
Short-term operating lease liability | 76 | 151 |
Total current liabilities | 97,202 | 104,505 |
Long-term accrued income taxes payable | 10,869 | 10,307 |
Total liabilities | 108,071 | 114,812 |
Commitments and contingencies (Note 4) | ||
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 133 | 133 |
Treasury stock | (641,059) | (635,078) |
Additional paid-in capital | 758,244 | 738,515 |
Accumulated other comprehensive income | 258 | 609 |
Retained earnings | 430,288 | 402,526 |
Total stockholders’ equity | 547,864 | 506,705 |
Total liabilities and stockholders’ equity | $ 655,935 | $ 621,517 |